Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.
BACKGROUND
Prader-Willi syndrome (PWS) is a multisystem genetic disorder characterized by short stature, muscular hypotonia, hyperphagia, obesity, maladaptive behaviour, hypogonadism and partial growth hormone (GH) deficiency (GHD). Severe GHD of other aetiologies has been shown to affect mood and quality of life negatively, and there are reports of improvements with GH replacement. We have studied cognitive, emotional, physical and social parameters in PWS adults at baseline, during and after GH treatment.


METHODS
Nineteen patients, 9 females and 10 males, median age 25 years, mean BMI 35 kg/m2 participated in this study. Approximately half of the group had GHD. All patients fulfilled the clinical criteria for PWS and 13 had a positive genotype. The patients were randomized to 6 months of treatment with either GH [1.6 IU/day (0.53 mg/day)] or placebo, followed by 12 months of active GH treatment. Treatment was then stopped, and the patients were followed for an additional period of 6 months. A test battery for general cognitive evaluation and a computer-based measurement of reaction time, motor speed and fluency were employed at baseline, after 6 months and at the end of GH treatment. At the same time intervals, a self-evaluation questionnaire was answered at the end of each test session. Other questionnaires reflecting the patients' cognitive, emotional, physical and social status were answered by relatives/caretakers at baseline and at 3 and 6 months following cessation of GH treatment.


RESULTS
Baseline cognitive level was estimated to be moderately to mildly impaired; IQ range was 40-90. The results from some of the cognitive and the motor performance tests improved significantly after 6 and 18 months of GH treatment. According to the questionnaires, both the patients and the relatives/caretakers evaluated physical status rather negatively at baseline, but still, impairments in both physical and social status and overall functioning were observed when GH treatment was discontinued. The self-evaluation did not change in any aspect during GH treatment.


CONCLUSIONS
In this pilot study of an adult PWS cohort, we were able to document beneficial effects in mental speed and flexibility and in motor performance during GH treatment. Impairment was seen in physical and social status as well as overall functioning, when GH treatment stopped. Studies of larger cohorts are needed to further elucidate the role of GH treatment in this group of patients.
Höybye
C
C
Department of Endocrinology and Diabetology, Karolinska Hospital, Stockholm, Sweden. charlotte.hoybye@ks.se
Thorén
M
M
Böhm
B
B
D000328:Adult; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D019382:Human Growth Hormone / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010865:Pilot Projects; D011218:Prader-Willi Syndrome / Q000188:drug therapy*; D011584:Psychology; D011597:Psychomotor Performance / Q000187:drug effects*; D011618:Psychotic Disorders / Q000175:diagnosis / Q000209:etiology*; D011788:Quality of Life / Q000523:psychology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D019382:Human Growth Hormone